Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: An interrupted time series analysis
04 July 2021
We assessed the impact of the coronavirus disease 2019 (COVID-19) epidemic in India on the consumption of antibiotics and hydroxychloroquine (HCQ) in the private sector in 2020 compared to the expected level of use had the epidemic not occurred.
A significant increase in non-CAF antibiotic sales, and particularly azithromycin, occurred during the peak phase of the first COVID-19 epidemic wave in India, indicating the need for urgent antibiotic stewardship measures.
Further reading: PLOS Medicine
Author(s): Giorgia Sulis, Brice Batomen, Anita Kotwani, Madhukar Pai, Sumanth Gandra
Effective Surveillance
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Every two weeks in your inbox
Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!